Analyst nearly doubles price target between Gocovri pricing and better prospects in Multiple Sclerosis arena.
Lead asset for ADMS indicates promising prospects in Parkinson’s along with valuable opportunity in MS.
Mizuho expects limited upside potential; Guggenheim lifts price target on AAPL, predicting key upside ahead.
We would be buyers of Micron approaching the FQ3 print and Apple event, says top analyst.
Irina Rivkind Koffler Doubles Down on Bearish Bet
Adamas Puts CRL Fears to Rest with Gocovri (Amantadine) Approval
Mizuho analyst Irina Rivkind Koffler came out today with new research notes on a handful of biotechnology stocks. Let’s take a look and …
Eagle Pharmaceuticals Inc (NASDAQ:EGRX) shares are on an almost 24% cave-in today after the biotech firm’s leading pipeline program, the one the Eagle …
Advanced Micro Devices, Inc. (NASDAQ:AMD) shares are taking off 10% in pre-market trading following a stellar second-quarterly print showing this chip giant is …
Horizon Pharma PLC (NASDAQ:HZNP) investors scurried sending shares crashing 35% yesterday once the biotech firm released disappointing first quarter earnings for the year …
